The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Tumour Vaccine Market Research Report 2025
Synopsis
The global Tumour Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Tumour Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumour Vaccine.
Report Scope
The Tumour Vaccine market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Tumour Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Tumour Vaccine companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Merck & Co Inc
Eli Lilly and Company
BioNTech
Roche Holding AG
OSE Immunotherapeutics
Gritstone Bio
Moderna
Avidea Technologies
Vaccibody AS
Agenus Inc
Novogene
ZIOPHARM Oncology
ISA Pharmaceuticals
BrightPath Biotherapeutics
Vaximm AG
Medigene AG
Genocea Biosciences Inc
Advaxis
Nouscom
Segment by Type
Personalized Vaccine
Off-the shelf Vaccine
Segment by Application
Lung Cancer
Melanoma Cancer
Gastrointestinal Cancer
Brain Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Tumour Vaccine companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Tumour Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Tumour Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumour Vaccine.
Report Scope
The Tumour Vaccine market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Tumour Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Tumour Vaccine companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Merck & Co Inc
Eli Lilly and Company
BioNTech
Roche Holding AG
OSE Immunotherapeutics
Gritstone Bio
Moderna
Avidea Technologies
Vaccibody AS
Agenus Inc
Novogene
ZIOPHARM Oncology
ISA Pharmaceuticals
BrightPath Biotherapeutics
Vaximm AG
Medigene AG
Genocea Biosciences Inc
Advaxis
Nouscom
Segment by Type
Personalized Vaccine
Off-the shelf Vaccine
Segment by Application
Lung Cancer
Melanoma Cancer
Gastrointestinal Cancer
Brain Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Tumour Vaccine companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Tumour Vaccine Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Personalized Vaccine
1.2.3 Off-the shelf Vaccine
1.3 Market by Application
1.3.1 Global Tumour Vaccine Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Lung Cancer
1.3.3 Melanoma Cancer
1.3.4 Gastrointestinal Cancer
1.3.5 Brain Cancer
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Tumour Vaccine Market Perspective (2019-2030)
2.2 Tumour Vaccine Growth Trends by Region
2.2.1 Global Tumour Vaccine Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Tumour Vaccine Historic Market Size by Region (2019-2024)
2.2.3 Tumour Vaccine Forecasted Market Size by Region (2025-2030)
2.3 Tumour Vaccine Market Dynamics
2.3.1 Tumour Vaccine Industry Trends
2.3.2 Tumour Vaccine Market Drivers
2.3.3 Tumour Vaccine Market Challenges
2.3.4 Tumour Vaccine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Tumour Vaccine Players by Revenue
3.1.1 Global Top Tumour Vaccine Players by Revenue (2019-2024)
3.1.2 Global Tumour Vaccine Revenue Market Share by Players (2019-2024)
3.2 Global Tumour Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Tumour Vaccine Revenue
3.4 Global Tumour Vaccine Market Concentration Ratio
3.4.1 Global Tumour Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tumour Vaccine Revenue in 2023
3.5 Tumour Vaccine Key Players Head office and Area Served
3.6 Key Players Tumour Vaccine Product Solution and Service
3.7 Date of Enter into Tumour Vaccine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Tumour Vaccine Breakdown Data by Type
4.1 Global Tumour Vaccine Historic Market Size by Type (2019-2024)
4.2 Global Tumour Vaccine Forecasted Market Size by Type (2025-2030)
5 Tumour Vaccine Breakdown Data by Application
5.1 Global Tumour Vaccine Historic Market Size by Application (2019-2024)
5.2 Global Tumour Vaccine Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Tumour Vaccine Market Size (2019-2030)
6.2 North America Tumour Vaccine Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Tumour Vaccine Market Size by Country (2019-2024)
6.4 North America Tumour Vaccine Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Tumour Vaccine Market Size (2019-2030)
7.2 Europe Tumour Vaccine Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Tumour Vaccine Market Size by Country (2019-2024)
7.4 Europe Tumour Vaccine Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Tumour Vaccine Market Size (2019-2030)
8.2 Asia-Pacific Tumour Vaccine Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Tumour Vaccine Market Size by Region (2019-2024)
8.4 Asia-Pacific Tumour Vaccine Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Tumour Vaccine Market Size (2019-2030)
9.2 Latin America Tumour Vaccine Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Tumour Vaccine Market Size by Country (2019-2024)
9.4 Latin America Tumour Vaccine Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Tumour Vaccine Market Size (2019-2030)
10.2 Middle East & Africa Tumour Vaccine Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Tumour Vaccine Market Size by Country (2019-2024)
10.4 Middle East & Africa Tumour Vaccine Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Tumour Vaccine Introduction
11.1.4 Pfizer Revenue in Tumour Vaccine Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Merck & Co Inc
11.2.1 Merck & Co Inc Company Detail
11.2.2 Merck & Co Inc Business Overview
11.2.3 Merck & Co Inc Tumour Vaccine Introduction
11.2.4 Merck & Co Inc Revenue in Tumour Vaccine Business (2019-2024)
11.2.5 Merck & Co Inc Recent Development
11.3 Eli Lilly and Company
11.3.1 Eli Lilly and Company Company Detail
11.3.2 Eli Lilly and Company Business Overview
11.3.3 Eli Lilly and Company Tumour Vaccine Introduction
11.3.4 Eli Lilly and Company Revenue in Tumour Vaccine Business (2019-2024)
11.3.5 Eli Lilly and Company Recent Development
11.4 BioNTech
11.4.1 BioNTech Company Detail
11.4.2 BioNTech Business Overview
11.4.3 BioNTech Tumour Vaccine Introduction
11.4.4 BioNTech Revenue in Tumour Vaccine Business (2019-2024)
11.4.5 BioNTech Recent Development
11.5 Roche Holding AG
11.5.1 Roche Holding AG Company Detail
11.5.2 Roche Holding AG Business Overview
11.5.3 Roche Holding AG Tumour Vaccine Introduction
11.5.4 Roche Holding AG Revenue in Tumour Vaccine Business (2019-2024)
11.5.5 Roche Holding AG Recent Development
11.6 OSE Immunotherapeutics
11.6.1 OSE Immunotherapeutics Company Detail
11.6.2 OSE Immunotherapeutics Business Overview
11.6.3 OSE Immunotherapeutics Tumour Vaccine Introduction
11.6.4 OSE Immunotherapeutics Revenue in Tumour Vaccine Business (2019-2024)
11.6.5 OSE Immunotherapeutics Recent Development
11.7 Gritstone Bio
11.7.1 Gritstone Bio Company Detail
11.7.2 Gritstone Bio Business Overview
11.7.3 Gritstone Bio Tumour Vaccine Introduction
11.7.4 Gritstone Bio Revenue in Tumour Vaccine Business (2019-2024)
11.7.5 Gritstone Bio Recent Development
11.8 Moderna
11.8.1 Moderna Company Detail
11.8.2 Moderna Business Overview
11.8.3 Moderna Tumour Vaccine Introduction
11.8.4 Moderna Revenue in Tumour Vaccine Business (2019-2024)
11.8.5 Moderna Recent Development
11.9 Avidea Technologies
11.9.1 Avidea Technologies Company Detail
11.9.2 Avidea Technologies Business Overview
11.9.3 Avidea Technologies Tumour Vaccine Introduction
11.9.4 Avidea Technologies Revenue in Tumour Vaccine Business (2019-2024)
11.9.5 Avidea Technologies Recent Development
11.10 Vaccibody AS
11.10.1 Vaccibody AS Company Detail
11.10.2 Vaccibody AS Business Overview
11.10.3 Vaccibody AS Tumour Vaccine Introduction
11.10.4 Vaccibody AS Revenue in Tumour Vaccine Business (2019-2024)
11.10.5 Vaccibody AS Recent Development
11.11 Agenus Inc
11.11.1 Agenus Inc Company Detail
11.11.2 Agenus Inc Business Overview
11.11.3 Agenus Inc Tumour Vaccine Introduction
11.11.4 Agenus Inc Revenue in Tumour Vaccine Business (2019-2024)
11.11.5 Agenus Inc Recent Development
11.12 Novogene
11.12.1 Novogene Company Detail
11.12.2 Novogene Business Overview
11.12.3 Novogene Tumour Vaccine Introduction
11.12.4 Novogene Revenue in Tumour Vaccine Business (2019-2024)
11.12.5 Novogene Recent Development
11.13 ZIOPHARM Oncology
11.13.1 ZIOPHARM Oncology Company Detail
11.13.2 ZIOPHARM Oncology Business Overview
11.13.3 ZIOPHARM Oncology Tumour Vaccine Introduction
11.13.4 ZIOPHARM Oncology Revenue in Tumour Vaccine Business (2019-2024)
11.13.5 ZIOPHARM Oncology Recent Development
11.14 ISA Pharmaceuticals
11.14.1 ISA Pharmaceuticals Company Detail
11.14.2 ISA Pharmaceuticals Business Overview
11.14.3 ISA Pharmaceuticals Tumour Vaccine Introduction
11.14.4 ISA Pharmaceuticals Revenue in Tumour Vaccine Business (2019-2024)
11.14.5 ISA Pharmaceuticals Recent Development
11.15 BrightPath Biotherapeutics
11.15.1 BrightPath Biotherapeutics Company Detail
11.15.2 BrightPath Biotherapeutics Business Overview
11.15.3 BrightPath Biotherapeutics Tumour Vaccine Introduction
11.15.4 BrightPath Biotherapeutics Revenue in Tumour Vaccine Business (2019-2024)
11.15.5 BrightPath Biotherapeutics Recent Development
11.16 Vaximm AG
11.16.1 Vaximm AG Company Detail
11.16.2 Vaximm AG Business Overview
11.16.3 Vaximm AG Tumour Vaccine Introduction
11.16.4 Vaximm AG Revenue in Tumour Vaccine Business (2019-2024)
11.16.5 Vaximm AG Recent Development
11.17 Medigene AG
11.17.1 Medigene AG Company Detail
11.17.2 Medigene AG Business Overview
11.17.3 Medigene AG Tumour Vaccine Introduction
11.17.4 Medigene AG Revenue in Tumour Vaccine Business (2019-2024)
11.17.5 Medigene AG Recent Development
11.18 Genocea Biosciences Inc
11.18.1 Genocea Biosciences Inc Company Detail
11.18.2 Genocea Biosciences Inc Business Overview
11.18.3 Genocea Biosciences Inc Tumour Vaccine Introduction
11.18.4 Genocea Biosciences Inc Revenue in Tumour Vaccine Business (2019-2024)
11.18.5 Genocea Biosciences Inc Recent Development
11.19 Advaxis
11.19.1 Advaxis Company Detail
11.19.2 Advaxis Business Overview
11.19.3 Advaxis Tumour Vaccine Introduction
11.19.4 Advaxis Revenue in Tumour Vaccine Business (2019-2024)
11.19.5 Advaxis Recent Development
11.20 Nouscom
11.20.1 Nouscom Company Detail
11.20.2 Nouscom Business Overview
11.20.3 Nouscom Tumour Vaccine Introduction
11.20.4 Nouscom Revenue in Tumour Vaccine Business (2019-2024)
11.20.5 Nouscom Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Tumour Vaccine Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Personalized Vaccine
Table 3. Key Players of Off-the shelf Vaccine
Table 4. Global Tumour Vaccine Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Tumour Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Tumour Vaccine Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Tumour Vaccine Market Share by Region (2019-2024)
Table 8. Global Tumour Vaccine Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Tumour Vaccine Market Share by Region (2025-2030)
Table 10. Tumour Vaccine Market Trends
Table 11. Tumour Vaccine Market Drivers
Table 12. Tumour Vaccine Market Challenges
Table 13. Tumour Vaccine Market Restraints
Table 14. Global Tumour Vaccine Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Tumour Vaccine Market Share by Players (2019-2024)
Table 16. Global Top Tumour Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumour Vaccine as of 2023)
Table 17. Ranking of Global Top Tumour Vaccine Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Tumour Vaccine Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Tumour Vaccine Product Solution and Service
Table 21. Date of Enter into Tumour Vaccine Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Tumour Vaccine Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Tumour Vaccine Revenue Market Share by Type (2019-2024)
Table 25. Global Tumour Vaccine Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Tumour Vaccine Revenue Market Share by Type (2025-2030)
Table 27. Global Tumour Vaccine Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Tumour Vaccine Revenue Market Share by Application (2019-2024)
Table 29. Global Tumour Vaccine Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Tumour Vaccine Revenue Market Share by Application (2025-2030)
Table 31. North America Tumour Vaccine Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Tumour Vaccine Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Tumour Vaccine Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Tumour Vaccine Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Tumour Vaccine Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Tumour Vaccine Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Tumour Vaccine Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Tumour Vaccine Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Tumour Vaccine Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Tumour Vaccine Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Tumour Vaccine Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Tumour Vaccine Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Tumour Vaccine Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Tumour Vaccine Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Tumour Vaccine Market Size by Country (2025-2030) & (US$ Million)
Table 46. Pfizer Company Detail
Table 47. Pfizer Business Overview
Table 48. Pfizer Tumour Vaccine Product
Table 49. Pfizer Revenue in Tumour Vaccine Business (2019-2024) & (US$ Million)
Table 50. Pfizer Recent Development
Table 51. Merck & Co Inc Company Detail
Table 52. Merck & Co Inc Business Overview
Table 53. Merck & Co Inc Tumour Vaccine Product
Table 54. Merck & Co Inc Revenue in Tumour Vaccine Business (2019-2024) & (US$ Million)
Table 55. Merck & Co Inc Recent Development
Table 56. Eli Lilly and Company Company Detail
Table 57. Eli Lilly and Company Business Overview
Table 58. Eli Lilly and Company Tumour Vaccine Product
Table 59. Eli Lilly and Company Revenue in Tumour Vaccine Business (2019-2024) & (US$ Million)
Table 60. Eli Lilly and Company Recent Development
Table 61. BioNTech Company Detail
Table 62. BioNTech Business Overview
Table 63. BioNTech Tumour Vaccine Product
Table 64. BioNTech Revenue in Tumour Vaccine Business (2019-2024) & (US$ Million)
Table 65. BioNTech Recent Development
Table 66. Roche Holding AG Company Detail
Table 67. Roche Holding AG Business Overview
Table 68. Roche Holding AG Tumour Vaccine Product
Table 69. Roche Holding AG Revenue in Tumour Vaccine Business (2019-2024) & (US$ Million)
Table 70. Roche Holding AG Recent Development
Table 71. OSE Immunotherapeutics Company Detail
Table 72. OSE Immunotherapeutics Business Overview
Table 73. OSE Immunotherapeutics Tumour Vaccine Product
Table 74. OSE Immunotherapeutics Revenue in Tumour Vaccine Business (2019-2024) & (US$ Million)
Table 75. OSE Immunotherapeutics Recent Development
Table 76. Gritstone Bio Company Detail
Table 77. Gritstone Bio Business Overview
Table 78. Gritstone Bio Tumour Vaccine Product
Table 79. Gritstone Bio Revenue in Tumour Vaccine Business (2019-2024) & (US$ Million)
Table 80. Gritstone Bio Recent Development
Table 81. Moderna Company Detail
Table 82. Moderna Business Overview
Table 83. Moderna Tumour Vaccine Product
Table 84. Moderna Revenue in Tumour Vaccine Business (2019-2024) & (US$ Million)
Table 85. Moderna Recent Development
Table 86. Avidea Technologies Company Detail
Table 87. Avidea Technologies Business Overview
Table 88. Avidea Technologies Tumour Vaccine Product
Table 89. Avidea Technologies Revenue in Tumour Vaccine Business (2019-2024) & (US$ Million)
Table 90. Avidea Technologies Recent Development
Table 91. Vaccibody AS Company Detail
Table 92. Vaccibody AS Business Overview
Table 93. Vaccibody AS Tumour Vaccine Product
Table 94. Vaccibody AS Revenue in Tumour Vaccine Business (2019-2024) & (US$ Million)
Table 95. Vaccibody AS Recent Development
Table 96. Agenus Inc Company Detail
Table 97. Agenus Inc Business Overview
Table 98. Agenus Inc Tumour Vaccine Product
Table 99. Agenus Inc Revenue in Tumour Vaccine Business (2019-2024) & (US$ Million)
Table 100. Agenus Inc Recent Development
Table 101. Novogene Company Detail
Table 102. Novogene Business Overview
Table 103. Novogene Tumour Vaccine Product
Table 104. Novogene Revenue in Tumour Vaccine Business (2019-2024) & (US$ Million)
Table 105. Novogene Recent Development
Table 106. ZIOPHARM Oncology Company Detail
Table 107. ZIOPHARM Oncology Business Overview
Table 108. ZIOPHARM Oncology Tumour Vaccine Product
Table 109. ZIOPHARM Oncology Revenue in Tumour Vaccine Business (2019-2024) & (US$ Million)
Table 110. ZIOPHARM Oncology Recent Development
Table 111. ISA Pharmaceuticals Company Detail
Table 112. ISA Pharmaceuticals Business Overview
Table 113. ISA Pharmaceuticals Tumour Vaccine Product
Table 114. ISA Pharmaceuticals Revenue in Tumour Vaccine Business (2019-2024) & (US$ Million)
Table 115. ISA Pharmaceuticals Recent Development
Table 116. BrightPath Biotherapeutics Company Detail
Table 117. BrightPath Biotherapeutics Business Overview
Table 118. BrightPath Biotherapeutics Tumour Vaccine Product
Table 119. BrightPath Biotherapeutics Revenue in Tumour Vaccine Business (2019-2024) & (US$ Million)
Table 120. BrightPath Biotherapeutics Recent Development
Table 121. Vaximm AG Company Detail
Table 122. Vaximm AG Business Overview
Table 123. Vaximm AG Tumour Vaccine Product
Table 124. Vaximm AG Revenue in Tumour Vaccine Business (2019-2024) & (US$ Million)
Table 125. Vaximm AG Recent Development
Table 126. Medigene AG Company Detail
Table 127. Medigene AG Business Overview
Table 128. Medigene AG Tumour Vaccine Product
Table 129. Medigene AG Revenue in Tumour Vaccine Business (2019-2024) & (US$ Million)
Table 130. Medigene AG Recent Development
Table 131. Genocea Biosciences Inc Company Detail
Table 132. Genocea Biosciences Inc Business Overview
Table 133. Genocea Biosciences Inc Tumour Vaccine Product
Table 134. Genocea Biosciences Inc Revenue in Tumour Vaccine Business (2019-2024) & (US$ Million)
Table 135. Genocea Biosciences Inc Recent Development
Table 136. Advaxis Company Detail
Table 137. Advaxis Business Overview
Table 138. Advaxis Tumour Vaccine Product
Table 139. Advaxis Revenue in Tumour Vaccine Business (2019-2024) & (US$ Million)
Table 140. Advaxis Recent Development
Table 141. Nouscom Company Detail
Table 142. Nouscom Business Overview
Table 143. Nouscom Tumour Vaccine Product
Table 144. Nouscom Revenue in Tumour Vaccine Business (2019-2024) & (US$ Million)
Table 145. Nouscom Recent Development
Table 146. Research Programs/Design for This Report
Table 147. Key Data Information from Secondary Sources
Table 148. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Tumour Vaccine Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Tumour Vaccine Market Share by Type: 2023 VS 2030
Figure 3. Personalized Vaccine Features
Figure 4. Off-the shelf Vaccine Features
Figure 5. Global Tumour Vaccine Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Tumour Vaccine Market Share by Application: 2023 VS 2030
Figure 7. Lung Cancer Case Studies
Figure 8. Melanoma Cancer Case Studies
Figure 9. Gastrointestinal Cancer Case Studies
Figure 10. Brain Cancer Case Studies
Figure 11. Others Case Studies
Figure 12. Tumour Vaccine Report Years Considered
Figure 13. Global Tumour Vaccine Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Tumour Vaccine Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Tumour Vaccine Market Share by Region: 2023 VS 2030
Figure 16. Global Tumour Vaccine Market Share by Players in 2023
Figure 17. Global Top Tumour Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumour Vaccine as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Tumour Vaccine Revenue in 2023
Figure 19. North America Tumour Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Tumour Vaccine Market Share by Country (2019-2030)
Figure 21. United States Tumour Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Tumour Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Tumour Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Tumour Vaccine Market Share by Country (2019-2030)
Figure 25. Germany Tumour Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Tumour Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Tumour Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Tumour Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Tumour Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Tumour Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Tumour Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Tumour Vaccine Market Share by Region (2019-2030)
Figure 33. China Tumour Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Tumour Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Tumour Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Tumour Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Tumour Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Tumour Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Tumour Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Tumour Vaccine Market Share by Country (2019-2030)
Figure 41. Mexico Tumour Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Tumour Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Tumour Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Tumour Vaccine Market Share by Country (2019-2030)
Figure 45. Turkey Tumour Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Tumour Vaccine Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Pfizer Revenue Growth Rate in Tumour Vaccine Business (2019-2024)
Figure 48. Merck & Co Inc Revenue Growth Rate in Tumour Vaccine Business (2019-2024)
Figure 49. Eli Lilly and Company Revenue Growth Rate in Tumour Vaccine Business (2019-2024)
Figure 50. BioNTech Revenue Growth Rate in Tumour Vaccine Business (2019-2024)
Figure 51. Roche Holding AG Revenue Growth Rate in Tumour Vaccine Business (2019-2024)
Figure 52. OSE Immunotherapeutics Revenue Growth Rate in Tumour Vaccine Business (2019-2024)
Figure 53. Gritstone Bio Revenue Growth Rate in Tumour Vaccine Business (2019-2024)
Figure 54. Moderna Revenue Growth Rate in Tumour Vaccine Business (2019-2024)
Figure 55. Avidea Technologies Revenue Growth Rate in Tumour Vaccine Business (2019-2024)
Figure 56. Vaccibody AS Revenue Growth Rate in Tumour Vaccine Business (2019-2024)
Figure 57. Agenus Inc Revenue Growth Rate in Tumour Vaccine Business (2019-2024)
Figure 58. Novogene Revenue Growth Rate in Tumour Vaccine Business (2019-2024)
Figure 59. ZIOPHARM Oncology Revenue Growth Rate in Tumour Vaccine Business (2019-2024)
Figure 60. ISA Pharmaceuticals Revenue Growth Rate in Tumour Vaccine Business (2019-2024)
Figure 61. BrightPath Biotherapeutics Revenue Growth Rate in Tumour Vaccine Business (2019-2024)
Figure 62. Vaximm AG Revenue Growth Rate in Tumour Vaccine Business (2019-2024)
Figure 63. Medigene AG Revenue Growth Rate in Tumour Vaccine Business (2019-2024)
Figure 64. Genocea Biosciences Inc Revenue Growth Rate in Tumour Vaccine Business (2019-2024)
Figure 65. Advaxis Revenue Growth Rate in Tumour Vaccine Business (2019-2024)
Figure 66. Nouscom Revenue Growth Rate in Tumour Vaccine Business (2019-2024)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
